Maximizing Efficiency In Lentiviral Vector Manufacturing

Advancing cell and gene therapies requires flexible lentiviral vector manufacturing solutions that scale seamlessly from preclinical development to commercial supply. Supporting both ex vivo applications and next-generation in vivo therapies, a structured production framework utilizing a proven four-plasmid transient transfection system can accelerate the timeline from gene to clinic in as little as eight months.

Optimized suspension and adherent processes dramatically enhance manufacturing efficiency, delivering high infectious titers at bulk harvest and outstanding impurity clearance. This robust process architecture minimizes replication-competent lentivirus risks while ensuring up to 95% clearance of residual host cell proteins. Backed by extensive current good manufacturing practice experience and comprehensive analytical testing—including functional titers and genome integrity characterization—this integrated approach ensures batch-to-batch reproducibility and absolute regulatory readiness.

Explore how these scalable lentiviral solutions can streamline your clinical program.